• Product NameLY2811376
• Brief DescriptionInhibitors
• Purification99.77%
• Biological ActivityLY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.
• Target NameBACE inhibitor; Beta Amyloid inhibitor
• CAS No. 1194044-20-6
• Calculated MW 320.36
• Formulation C15H14F2N4S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Nervous system
  SMILES:C[C@]1(CCSC(=N1)N)C2=C(C=C(C(=C2)C3=CN=CN=C3)F)F
  Pathways:Neuroscience
  Receptor:BACE1; Aβ
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 64 mg/mL (199.77 mM); DMSO: 16 mg/mL (49.94 mM)
  Appearance:Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. May P, et al. J Neurosci, 2011, 31(46), 16507-16516.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting